5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      First Human Report of Relief of Lumbar and Cervical Discogenic and Arthritic Back Pain after Epidural and Facet Joint Mesenchymal Stem Cell Injection: A Case Report

      1 , 1 , 1 , 2
      Current Stem Cell Research & Therapy
      Bentham Science Publishers Ltd.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction:

          Back pain causes tremendous patient suffering and high financial cost to the healthcare system. Mesenchymal Stem Cells (MSCs) have demonstrated the ability to enhance healing and reduce inflammation and pain without the deleterious side effects of corticosteroids and nonsteroidal anti-inflammatory drugs in numerous clinical series for peripheral joint arthritis. We hypothesized that translaminar MSC injection into the epidural space would effectively treat disc arthritis without the burden of sedation and the risks of disc space injection. We further hypothesized that MSC injection into the facet joints would effectively and safely treat facet joint-induced back pain. The combination of epidural and facet joint injection would potentially treat the most recognized low back pain generators with virtually complete safety.

          Objective:

          We present the initial results for the first patient enrolled in phase 1 clinical trial of the efficacy and safety of allogeneic MSCs when injected translaminarly and into the facet joints for the treatment of recalcitrant discogenic and arthritic back pain.

          Case Report:

          A 47-year-old male presented with complaints of 13-year-long chronic lower back pain resistant to conservative treatment. The decision was made to treat the patient with umbilical cord-derived MSCs. 87 million MSCs were infused intravenously. Simultaneously, 1 million cells were injected into each of the 8 lumbar epidural facet joints and 5 million cells into the lumbar epidural space. The patient had no adverse events or complications related to the treatment. Five days after treatment, most of his lumbar pain was gone, and his back spasms stopped. He no longer needed to take acetaminophen or ibuprofen and had no difficulty sleeping without medications. The patient also reported his residual cervical radicular pain to be 98% resolved due to the injection.

          Conclusion:

          We have demonstrated for the first time that MSC injection into the lumbar facet joints and epidural space results in significant improvement of lower back pain and can improve symptoms in other spinal regions without engendering the risks associated with intradiscal injections or epidural use of corticosteroids.

          Related collections

          Most cited references14

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine

          Mesenchymal stem cells (MSCs) are partially defined by their ability to differentiate into tissues including bone, cartilage and adipose in vitro, but it is their trophic, paracrine and immunomodulatory functions that may have the greatest therapeutic impact in vivo. Unlike pharmaceutical treatments that deliver a single agent at a specific dose, MSCs are site regulated and secrete bioactive factors and signals at variable concentrations in response to local microenvironmental cues. Significant progress has been made in understanding the biochemical and metabolic mechanisms and feedback associated with MSC response. The anti-inflammatory and immunomodulatory capacity of MSC may be paramount in the restoration of localized or systemic conditions for normal healing and tissue regeneration. Allogeneic MSC treatments, categorized as a drug by regulatory agencies, have been widely pursued, but new studies demonstrate the efficacy of autologous MSC therapies, even for individuals affected by a disease state. Safety and regulatory concerns surrounding allogeneic cell preparations make autologous and minimally manipulated cell therapies an attractive option for many regenerative, anti-inflammatory and autoimmune applications.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Low back pain

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans.

              Adipose tissue-derived mesenchymal stem cells (AdMSCs) represent an attractive and ethical cell source for stem cell therapy. With the recent demonstration of MSC homing properties, intravenous applications of MSCs to cell-damaged diseases have increased. In the present study, the toxicity and tumorigenicity of human AdMSCs (hAdMSCs) were investigated for clinical application. Culture-expanded hAdMSCs showed the typical appearance, immunophenotype, and differentiation capacity of MSCs, and were genetically stable at least 12 passages in culture. Cells suspended in physiological saline maintained their MSC properties in a cold storage condition for at least 3 days. To test the toxicity of hAdMSCs, different doses of hAdMSCs were injected intravenously into immunodeficient mice, and the mice were observed for 13 weeks. Even at the highest cell dose (2.5×10(8) cells/kg body weight), the SCID mice were viable and had no side effects. A tumorigenicity test was performed in Balb/c-nu nude mice for 26 weeks. Even at the highest cell dose (2×10(8) MSCs/kg), no evidence of tumor development was found. In a human clinical trial, 8 male patients who had suffered a spinal cord injury >12 months previous were intravenously administered autologous hAdMSCs (4×10(8) cells) one time. None of the patients developed any serious adverse events related to hAdMSC transplantation during the 3-month follow-up. In conclusion, the systemic transplantation of hAdMSCs appears to be safe and does not induce tumor development.
                Bookmark

                Author and article information

                Journal
                Current Stem Cell Research & Therapy
                CSCR
                Bentham Science Publishers Ltd.
                1574888X
                August 2023
                August 2023
                : 18
                : 7
                : 1013-1015
                Affiliations
                [1 ]The Foundation for Orthopaedics and Regenerative Medicine, Glenview, 60025, IL, USA
                [2 ]Advocate Illinois Masonic Medical Center, Chicago, IL, USA
                Article
                10.2174/1574888X17666220628123115
                35762554
                aa19d685-035a-4374-887f-a0b48d2c4213
                © 2023
                History

                Comments

                Comment on this article